Avita Medical's ReCell proposal receives high rating from BARDA

Avita Medical, Ltd. announced Monday that a proposal to utilize its ReCell technology as a potential component to U.S. disaster preparedness programs has been given a high rating from federal officials.

Avita Medical said the Biomedical Advanced Research and Development Authority (BARDA) and the Acquisition Management, Contracts and Grants (AMCG) office informed the company that its proposal was "within competitive range." Avita Medical  said this is the highest rating a proposal of this kind can achieve.

The ReCell technology enables physicians to build regenerative epithelial suspension (RES) consisting of cells that have wound healing capabilities in order to provide a treatment option for healthy skin following trauma. The recovered skin cells would serve both aesthetic and functional properties of healthy skin derived from the patient. According to the announcement, the RES is capable of completion within 30 minutes.

"We welcome this response from BARDA and AMCG, and will now engage with BARDA to address their requests for further specific information," Avita Medical CEO Adam Kelliher said. "At the same time, we want to ensure that our constituents have all material company information available to them."

Avita Medical submitted its proposal at the end of July after BARDA had requested submissions for autograft-sparing products and technologies that would be able to enhance the care for thermal burn injuries.

 Avita could possibly receive funding from BARDA in order to develop their technology further.

Organizations in this Story

Avita Medical, Ltd

Want to get notified whenever we write about Avita Medical, Ltd ?
Next time we write about Avita Medical, Ltd, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.